Page last updated: 2024-10-21

2-hydroxysaclofen and Epilepsy, Absence

2-hydroxysaclofen has been researched along with Epilepsy, Absence in 3 studies

2-hydroxysaclofen: structure given in first source

Epilepsy, Absence: A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
von Krosigk, M1
Bal, T1
McCormick, DA1
Snead, OC1
Hosford, DA1
Clark, S1
Cao, Z1
Wilson, WA1
Lin, FH1
Morrisett, RA1
Huin, A1

Other Studies

3 other studies available for 2-hydroxysaclofen and Epilepsy, Absence

ArticleYear
Cellular mechanisms of a synchronized oscillation in the thalamus.
    Science (New York, N.Y.), 1993, Jul-16, Volume: 261, Issue:5119

    Topics: Animals; Baclofen; Bicuculline; Calcium; Epilepsy, Absence; Ferrets; Geniculate Bodies; In Vitro Tec

1993
Antiabsence seizure activity of specific GABAB and gamma-Hydroxybutyric acid receptor antagonists.
    Pharmacology, biochemistry, and behavior, 1996, Volume: 53, Issue:1

    Topics: Animals; Anticonvulsants; Baclofen; Benzocycloheptenes; Electroencephalography; Epilepsy, Absence; G

1996
The role of GABAB receptor activation in absence seizures of lethargic (lh/lh) mice.
    Science (New York, N.Y.), 1992, Jul-17, Volume: 257, Issue:5068

    Topics: Animals; Anticonvulsants; Baclofen; Disease Models, Animal; Dose-Response Relationship, Drug; Electr

1992